vs
AXCELIS TECHNOLOGIES INC（ACLS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
AXCELIS TECHNOLOGIES INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$238.3M vs $207.3M），AXCELIS TECHNOLOGIES INC净利率更高（14.4% vs -62.0%，领先76.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -5.6%），AXCELIS TECHNOLOGIES INC自由现金流更多（$-8.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -2.8%）
Axcelis Technologies是一家美国半导体设备供应商，1995年成立，总部位于美国马萨诸塞州贝弗利。公司面向全球半导体制造行业，从事半导体生产核心设备的设计、制造及服务，主营产品包括高中电流、高能离子注入系统以及半导体芯片制造用固化系统。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ACLS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $238.3M | $207.3M |
| 净利润 | $34.3M | $-128.6M |
| 毛利率 | 47.0% | — |
| 营业利润率 | 15.2% | -54.7% |
| 净利率 | 14.4% | -62.0% |
| 营收同比 | -5.6% | 25.9% |
| 净利润同比 | -31.3% | 3.5% |
| 每股收益（稀释后） | $1.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $238.3M | $207.3M | ||
| Q3 25 | $213.6M | $159.9M | ||
| Q2 25 | $194.5M | $166.5M | ||
| Q1 25 | $192.6M | $139.3M | ||
| Q4 24 | $252.4M | $164.6M | ||
| Q3 24 | $256.6M | $139.5M | ||
| Q2 24 | $256.5M | $147.0M | ||
| Q1 24 | $252.4M | $108.8M |
| Q4 25 | $34.3M | $-128.6M | ||
| Q3 25 | $26.0M | $-180.4M | ||
| Q2 25 | $31.4M | $-115.0M | ||
| Q1 25 | $28.6M | $-151.1M | ||
| Q4 24 | $50.0M | $-133.2M | ||
| Q3 24 | $48.6M | $-133.5M | ||
| Q2 24 | $50.9M | $-131.6M | ||
| Q1 24 | $51.6M | $-170.7M |
| Q4 25 | 47.0% | — | ||
| Q3 25 | 41.6% | — | ||
| Q2 25 | 44.9% | — | ||
| Q1 25 | 46.1% | — | ||
| Q4 24 | 46.0% | — | ||
| Q3 24 | 42.9% | — | ||
| Q2 24 | 43.8% | — | ||
| Q1 24 | 46.0% | — |
| Q4 25 | 15.2% | -54.7% | ||
| Q3 25 | 11.7% | -106.9% | ||
| Q2 25 | 14.9% | -64.8% | ||
| Q1 25 | 15.1% | -102.6% | ||
| Q4 24 | 21.6% | -74.3% | ||
| Q3 24 | 18.3% | -94.6% | ||
| Q2 24 | 20.6% | -79.1% | ||
| Q1 24 | 22.4% | -151.9% |
| Q4 25 | 14.4% | -62.0% | ||
| Q3 25 | 12.2% | -112.8% | ||
| Q2 25 | 16.1% | -69.0% | ||
| Q1 25 | 14.8% | -108.5% | ||
| Q4 24 | 19.8% | -80.9% | ||
| Q3 24 | 18.9% | -95.7% | ||
| Q2 24 | 19.8% | -89.5% | ||
| Q1 24 | 20.4% | -156.8% |
| Q4 25 | $1.11 | $-1.28 | ||
| Q3 25 | $0.83 | $-1.81 | ||
| Q2 25 | $0.98 | $-1.17 | ||
| Q1 25 | $0.88 | $-1.57 | ||
| Q4 24 | $1.54 | $-1.34 | ||
| Q3 24 | $1.49 | $-1.40 | ||
| Q2 24 | $1.55 | $-1.52 | ||
| Q1 24 | $1.57 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $374.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $374.3M | $421.0M | ||
| Q3 25 | $449.6M | $202.5M | ||
| Q2 25 | $549.8M | $176.3M | ||
| Q1 25 | $587.1M | $127.1M | ||
| Q4 24 | $571.3M | $174.0M | ||
| Q3 24 | $579.4M | $150.6M | ||
| Q2 24 | $548.3M | $480.7M | ||
| Q1 24 | $530.2M | $112.3M |
| Q4 25 | $1.0B | $-80.0M | ||
| Q3 25 | $1.0B | $9.2M | ||
| Q2 25 | $1.0B | $151.3M | ||
| Q1 25 | $1.0B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $975.6M | $346.8M | ||
| Q2 24 | $934.9M | $432.4M | ||
| Q1 24 | $901.7M | $140.3M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.3B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | -3.7% | -48.6% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | -0.19× | — |
| 过去12个月自由现金流最近4个季度 | $107.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-6.6M | $-99.8M | ||
| Q3 25 | $45.4M | $-91.4M | ||
| Q2 25 | $39.7M | $-108.3M | ||
| Q1 25 | $39.8M | $-166.5M | ||
| Q4 24 | $12.8M | $-79.3M | ||
| Q3 24 | $45.7M | $-67.0M | ||
| Q2 24 | $40.1M | $-77.0M | ||
| Q1 24 | $42.2M | $-190.7M |
| Q4 25 | $-8.9M | $-100.8M | ||
| Q3 25 | $43.3M | $-92.7M | ||
| Q2 25 | $37.7M | $-110.7M | ||
| Q1 25 | $34.8M | $-167.8M | ||
| Q4 24 | $8.1M | $-79.5M | ||
| Q3 24 | $41.8M | $-68.6M | ||
| Q2 24 | $38.1M | $-79.0M | ||
| Q1 24 | $40.6M | $-193.9M |
| Q4 25 | -3.7% | -48.6% | ||
| Q3 25 | 20.3% | -58.0% | ||
| Q2 25 | 19.4% | -66.5% | ||
| Q1 25 | 18.1% | -120.5% | ||
| Q4 24 | 3.2% | -48.3% | ||
| Q3 24 | 16.3% | -49.2% | ||
| Q2 24 | 14.8% | -53.7% | ||
| Q1 24 | 16.1% | -178.2% |
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 2.6% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 0.8% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
| Q4 25 | -0.19× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
